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The heart and the kidneys share responsibility for maintaining hemodynamic stability and end-organ perfusion. Connections
between these organs ensure that subtle physiologic changes in one system are tempered by compensation in the other through a
variety of pathways and mediators. In the setting of underlying heart disease or chronic kidney disease, the capacity of each organ
to respond to perturbation caused by the other may become compromised. This has recently led to the characterization of the
cardiorenal syndrome (CRS). This review will primarily focus on CRS type 1 where acute decompensated heart failure (ADHF)
results in activation of hemodynamic and neurohormonal factors leading to an acute drop in the glomerular ﬁltration rate and
the development of acute kidney injury. We will examine the scope and impact of this problem, the pathophysiology associated
with this relationship, including underperfuson and venous congestion, diagnostic tools for earlier detection, and therapeutic
interventions to prevent and treat this complication.
1.Introduction
The heart and the kidneys share responsibility for maintain-
inghemodynamicstabilityandend-organperfusionthrough
atight-knitrelationshipthatcontrolscardiacoutput,volume
status, and vascular tone. Connections between these organs
ensurethatsubtlephysiologicchangesinonesystemaretem-
pered by compensation in the other. As such, hemodynamic
control remains stable through a wide range of physiologic
conditions.
Communication between the heart and kidneys occurs
through a variety of pathways. These include perfusion pres-
sure, ﬁlling pressure, and neurohormonal activity. In par-
ticular, some of the key mediators include the sympathetic
nervous system, the renin-angiotensin-aldosterone axis, and
atrial natriuretic peptide. These agents have receptors in the
heart, the kidneys, and the vasculature that aﬀect volume
status, vascular tone, cardiac output, and inotropy. A change
in the performance of one of these organs elicits a cascade of
mediators that aﬀects the other.
In the setting of underlying heart disease or chronic
kidney disease, the capacity of each organ to respond to
perturbationcausedbytheothermaybecomecompromised.
Acute or chronic heart failure may push the kidneys beyond
their ability to maintain glomerular ﬁltration, regulate ﬂuid
and electrolytes, and clear metabolic waste. Similarly, acute
kidney injury or chronic kidney disease aﬀects cardiac
performance through electrolyte dysequilibration, volume
overload, and negative inotropy. Clinical, cardiac, and renal
parameters associated with dysfunction in the other organ
are identiﬁed in Table 1.
This special relationship and the interdependence of the
kidneys and the heart is well recognized. The manner in
which dysfunction of one organ aﬀects the other has recently
led to the characterization of the cardiorenal syndrome
(CRS). At a consensus conference of the Acute Dialysis
Quality Initiative (ADQI), the cardiorenal syndrome was
subclassiﬁed into 5 types [2] based upon the organ that
initiated the insult as well as the acuity or chronicity of the
precipitating event. The classiﬁcation system for the CRS is
outlined in Table 2.
This review will primarily focus on CRS type 1, where
acute cardiac decompensation results in activation of hemo-
dynamic and neurohormonal factors that lead to an acute
drop in GFR and the development of AKI. We will examine
the scope and impact of this problem, the pathophysiology2 International Journal of Nephrology
Table 1: Risk factors for the cardiorenal syndrome [1].
Clinical
(i) Older age
(ii) Comorbid conditions (diabetes mellitus, uncontrolled hypertension, and anemia
(iii) Drugs
(a) Antiinﬂammatory agents
(b) Diuretics (thiazides, loop diuretics)
(c) Angiotensin converting enzyme inhibitors/angiotensin receptor blockers
(d) Aldosterone receptor antagonists
Heart
(i) History of heart failure or impaired left ventricular ejection fraction
(ii) Prior myocardial infection
(iii) New York Hear Association functional class
(iv) Elevated cardiac troponin
Kidney
(i) Chronic kidney disease (reduced eGFR, elevated BUN, creatinine, or cystatin)
Table 2: ADQI classiﬁcation system of the cardiorenal syndrome [2].
Inciting event Secondary disturbance
CRS type 1 Acute decompensated heart failure Acute kidney injury
CRS type 2 Chronic heart failure Chronic kidney disease
CRS type 3 Acute kidney injury Acute heart failure
CRS type 4 Chronic kidney disease Chronic heart failure
CRS type 5 Codevelopment of heart failure and chronic kidney disease
associated with this relationship, diagnostic clues for earlier
detection, and therapeutic interventions to prevent and treat
this complication.
2. Epidemiology
Heart failure is a common chronic condition aﬀecting 2%
of the adult population [3] and resulting in over 1 million
annual admissions [4], making it the leading cause of
hospitalization in the United States among adults over the
age of 65. Health expenditures for heart failure in 2008
exceeded $35 billion dollars [5]. Acute kidney injury may
complicate one-third of these admissions, resulting in a
three fold increase in length of stay, a greater likelihood for
hospital readmission, and a 22% higher mortality rate [6–9].
This reduction in outcomes occurs with increases in serum
creatinine of as little as 0.33mg/dl, regardless of its presence
at admission or its development during the course of heart
failure treatment [10, 11]
In addition, approximately 25% of patients with chronic
heart failure have been found to have reduced GFR [12],
independent of their level of left ventricular function
[13]. A prospective cohort of 754 patients with chronic
heart failure found only 17% of patients had an eGFR >
90ml/min [14]. In the large Acute Decompensated Heart
Failure National Registry (ADHERE), reduced GFR aﬀected
30% of the 107,362 individuals [15]. Furthermore, 21% of
patients had serum creatinine concentrations > 2mg/dl,and
9% had serum creatinine concentrations > 3mg/dl [16].
This reduction in kidney function has signiﬁcant impact
on both morbidity and mortality [17, 18]. In a meta-
analysis of 80,098 hospitalized and nonhospitalized patients,
an eGFR < 53ml/min was associated with a 51% 1-year
mortality compared to a 38% 1-year mortality for an eGFR
< 90ml/min. Preserved kidney function with an eGFR >
90ml/min was associated with a 24% 1-year mortality [19].
3. Physiology of the CardiorenalAxis
The heart, by way of regulating the systemic circulation,
and the kidneys, through their eﬀect on extracellular ﬂuid
volume, share responsibility for the hemodynamic balance
in the body. The kidneys produce a glomerular ﬁltrate
that is dependent upon perfusion pressure and aﬀerent
and eﬀerent arteriolar tone. The arteriolar resistance is
under intrinsic myogenic control, and responsive to several
neurohormonal systems. The renin-angiotensin-aldosterone
system (RAAS), the sympathetic nervous system (SNS), and
local vasodilators such as nitric oxide (NO), adenosine, and
prostaglandins contribute to maintaining the glomerular
ﬁltration rate (GFR) through conditions of increased or
decreased perfusion pressure. When renal perfusion pressure
decreases, angiotensin II (AII) preferentially increases the
eﬀerent arteriolar resistance to preserve intraglomerular
hydrostatic pressure and maintain GFR. Simultaneously, the
aﬀerent arteriole, under control of tubuloglomerular feed-
back and prostaglandins, dilates to increase the transmission
of perfusion pressure into the glomerulus. An elegant systemInternational Journal of Nephrology 3
senses decreased glomerular perfusion from hypovolemia
or decreased cardiac output at the macula densa and the
juxtaglomerular apparatus, then activates the RAAS, nitric
oxide, adenosine, and prostaglandin production to prevent
dramatic changes in kidney function.
We will now explore some of the mechanisms that eﬀect
kidney function during decompensated heart failure.
3.1. Underperfusion. Acute decompensated heart failure
(ADHF) results in reduced eﬀective arterial ﬁlling volume
(EAFV) [20]. This decreased EAFV diminishes renal blood
ﬂow and subsequently renal perfusion pressure. Decreased
tubular sodium and chloride delivery is sensed by the
macula densa and the juxtaglomerular apparatus, activating
the RAAS. RAAS enhances sodium and water retention
to increase EAFV and stroke volume, but comes at the
detrimental cost of volume overload. Furthermore, nore-
pinephrine is released in response to systemic hypoperfusion
sensedbybaroreceptors.Whereasangiotensincauseseﬀerent
arteriole constriction, norepinephrine induces both aﬀerent
and eﬀerent arteriole constriction and increases renal vas-
cular resistance. In a setting of low cardiac output, both
angiotensin and norepinephrine cause decreased renal blood
ﬂow (RBF), diverting blood to the coronary and cerebral
circulations. When the normal compensatory mechanisms
such as NO, bradykinin, adenosine, and prostaglandins are
unable to maintain GFR in the setting of decreased RBF, the
groundwork for renal ischemia is laid. It appears, therefore,
that the cardiovascular eﬀects on hemodynamics and the
renal eﬀects on extracellular ﬂuid volume are in constant
ﬂux.
An imbalance in this relationship results in the CRS. In
the setting of heart failure where low cardiac output and
anoveractiveneurohormonalsystempushthecompensatory
limits, a simple insult such as NSAIDS or aggressive diuresis
can precipitate acute kidney injury [21]. NSAIDs inhibit
the protective eﬀect of prostaglandins to dilate the aﬀerent
arteriole, while over diuresis might lead to further decreased
EAFV. Diuretics are eﬀective when properly dosed to allow
reequilibration of ﬂuid from the interstitial compartment
into the intravascular compartment. If the rate of diuresis
exceeds this shift, then kidney dysfunction occurs. Other
observations have suggested that RBF is the most important
determinant of GFR in patients with CHF [22].
3.2. Venous Congestion. W h i l ei ti st r u et h a td e c r e a s e d
forwardﬂowasaresultofdecreasedcardiacoutputinADHF
can cause acute deterioration in kidney function, there are
several reasons why this mechanism fails to completely
explain the development of the CRS. First, altered hemody-
namics alone are inadequate to explain the mechanism of
kidney injury in ADHF as redundant feedback mechanisms
exist to prevent it. Second, the CRS has been observed in
patients with diastolic dysfunction who have normal left
ventricular systolic function [14]. In the ADHERE registry,
acute kidney injury occurred at similar rates in patients with
both systolic and diastolic dysfunction [23]. And ﬁnally,
subgroup analysis of the ESCAPE trial showed evidence
that poor forward ﬂow alone was insuﬃcient to explain
worsening kidney function. In this trial, an improved cardiac
index was not associated with improved renal outcomes,
but increased CVP and atrial pressures were associated with
decreased kidney function [24].
Observations dating back to the 1930s have suggested
that renal venous congestion could also contribute to
decreased glomerular ﬁltration. Experiments conducted on
canine models revealed that increased venous pressure in
the kidneys caused changes in urinary sodium, chloride, and
urea excretion similar to decreased arterial pressure. Urine
ﬂow decreased when renal venous pressures were increased
to 20 mmHg. This also led to a drop in glomerular perfusion
pressure, and a reduction in GFR [25].It is hypothesized that
increased venous pressure distends the venules surrounding
the distal nephron. This leads to compression of the tubule,
increased tubular ﬂuid pressure, and backleak of ﬁltrate
into the interstitium. An increased interstitial pressure then
results in venous congestion and interstitial hypoxia [26].
Furthermore, as hydrostatic pressure within the Bowman’s
capsule increases, GFR fails and the RAAS is activated and
t h eS N Si st r i g g e r e d[ 27]. The sequence of events is shown in
Figure 1.
Studies in human subjects have also demonstrated that
increased central venous and right atrial pressure are asso-
ciated with worsening kidney function as well as increased
mortality [29, 30]. Damman and colleagues have demon-
strated that increased venous pressure is an independent
determinant of glomerular ﬁltration in patients with heart
failure[28]. Inthis studythelowestglomerularﬁltrationrate
was observed in patients with lowest renal blood ﬂow and
highest right atrial pressures.
3.3. Intra-Abdominal Hypertension. Intraabdominal hyper-
tension might be yet another mechanism contributing to
the CRS. Elevated intraabdominal pressure from ascites and
abdominal wall edema is also prevalent in patients with
ADHF, and associated with worsening kidney function [31].
Several studies have suggested that the deterioration in the
kidney function is not due to direct parenchymal pressure
on the kidneys, but rather due to elevated central venous
pressure, arterial underﬁlling, and renal venous congestion
[32, 33]. The decline in kidney function from increased
intraabdominal pressure is mechanistically related to the
venous congestion described above.
4. Mediatorsof the CardiorenalSyndrome
There are a variety of neurohormonal mediators associated
with the deterioration of kidney function in ADHF. Under-
standing these-mediators and eﬀectors yields insight into the
diagnosis and therapy of CRS.
4.1. Renin-Angiotensin-Aldosterone System. The CRS occurs
with both hypoperfusion associated with decreased cardiac
output as well as venous congestion. The actions of the
RAAS, beyond its role to maintain hemodynamics, may
explain this cardiorenal connection.4 International Journal of Nephrology
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Figure 1: Pathophysiology of the relation between venous congestion and reduced glomerular ﬁltration rate (GFR). Reprinted with
modiﬁcation from Damman et al. [28].
Activation of RAAS by hypoperfusion activates the
sympathetic nervous system (SNS) [34], and mediates the
release of reactive oxygen species (ROS) and mediators
of vascular inﬂammation [35]. Angiotensin II activates
both NADH-oxidase and NADPH-oxidase [36], which then
g e n e r a t e sr e a c t i v eo x y g e ns p e c i e s .S t u d i e sh a v ed e m o n -
strated this activity in vascular smooth muscle cells, cardiac
myocytes, and both renal tubular cells [37]a n dg l o m e r u l i
in the kidneys. ROS, speciﬁcally superoxides, have been
implicated in organ injury and inﬂammation. The ensuing
oxidative stress results in a proinﬂammatory state activating
chemokinessuchasIL-1,IL-6,andTNFalpha,andattracting
leucocytes. Furthermore, studies have shown that the eﬀect
of NADPH-oxidase mediated ROS release can be attenuated
by angiotensin converting enzyme (ACE) inhibition.
Angiotensin II also has a role in chemokine regulation
and monocyte recruitment. Angiotensin II increases Mono-
cyte Chemoattractant Protein-1 (MCP-1) in mesangial and
mononuclear cells by a mechanism dependent on nuclear
factor-κB( N F - κB) activation [38]. These monocytes and
chemokines play a major role in the propagation of kidney
injury [39]. Angiotensin II also activates the sympathetic
nervous system through its eﬀect on the vasomotor center in
the brain. This was established by showing increased muscle
sympathetic nerve activity (MSNA) in patients with kidney
failure [40]. Studies using ACE inhibitors and angiotensin
receptor blockers (ARB) have shown decreased MSNA and
decreased sympathetic activity [41, 42]. Thus AII seems to
play a direct role in renal injury [43] and direct damage to
the glomerular ﬁltration barrier [44, 45].
4.2. Nitric oxide and Reactive Oxygen Species Disequilib-
rium. Nitric oxide, an endothelium-derived relaxing fac-
tor, is a vasodilator that acts to regulate vascular tone,
blood pressure, and smooth muscle hypertrophy through
downregulation of ACE and the AII type 1 receptor. NO
therefore represents a physiologic antagonist of AII at both
the glomerular and tubular levels [46, 47]. It also plays
a role in tubuloglomerular feedback through dilation of
the aﬀerent arteriole [48]. In decompensated heart failure,
RAAS activation causes angiotensin mediated hypertension
through increased systemic vascular resistance, greater renal
perfusion pressure through preferential eﬀerent arterio-
lar vasoconstriction, and renal oxidative stress through
enhanced NADPH-oxidase activity in rats [49]. Reduced
activity of superoxide dismutase (SOD) is thought to be
involved in increased ROS generation. Subsequently, there
is a shift in the NO/ROS system to the ROS side. Several
factors contribute to this shift. In heart failure, asymmetric
dimethyl arginine (ADMA) levels are increased. ADMA is a
novelcardiovascularriskfactorthatdecreasesNOlevels[50].
Even mild heart failure is associated with decreased renal
perfusion by way of NO inhibition. Also, Endothelin I (ET 1)
is implicated in vasoconstriction, causing mesangial cell
contraction and mesangial cell mitogenesis [51]. Whereas
AII stimulates the release of ET 1, NO inhibits ET 1 release
from endothelial cells. An imbalance in favor of more
ET 1 production causes endothelial dysfunction as well as
glomerular and interstitial damage [52].
4.3. Other Mediators. Atrial natriuretic peptide (ANP) and
brain natriuretic peptide (BNP) are released in response to
stretch of the cardiac chambers, and play a role in regulation
of ECFV by inducing sodium and water loss. They are
elevated in both heart failure and reduced kidney function.
Although they are an ideal therapeutic target, their role in
the pathophysiology of CRS is not known.International Journal of Nephrology 5
Erythropoietin is purported to decrease apoptosis in
renalcellsandcardiacmyocytesbydecreasingoxidativestress
[53].Smalltrialshaverevealedthatheartfailurepatientswho
received erythropoietin had improved kidney function [54],
but their place in the treatment of CRS cannot be conﬁrmed
without long-term studies.
Antidiuretic hormone (ADH) levels are elevated in HF
due to nonosmotic stimuli from baroreceptor stimulation
[55]. Antagonism of ADH would seem to have a role in the
CRS,butstudiesofvasopressinreceptor2antagonistsdidnot
result in improvement in kidney function [56].
There is direct evidence to demonstrate that HF is
associated with tubulointerstitial damage. A recent study by
Dammanandcolleaguesshowedthatcongestiveheartfailure
is associated with increased markers of tubulointerstitial
damage such as N-acetyl-beta-D-glucosaminidase (NAG),
kidney injury molecule 1 (KIM-1), and neutrophil gelatinase
associated lipocalin (NGAL) [57]. Other studies have also
demonstrated renal tubular and interstitial damage as well
[58].
In summary, it appears that regardless of whether
decreased perfusion occurs as a result of hypoperfusion
or venous congestion, the consequent processes resulting
in kidney injury are the same. RAAS activation results
in increased AII which stimulates NADH and NADPH-
oxidases. The resulting NADPH/NADH suppresses super-
oxide dismutase, and increases reactive oxygen species. This
results in the well known cascade of hypoxic ischemic injury,
inﬂammation, apoptosis and cell death as shown in Figure 2.
5.Diagnosis
One of the cornerstones of CRS therapy is the early
identiﬁcation of worsening kidney function. This can be
accomplished with the use of biomarkers that become
detectable before the traditional tests for kidney function,
including glomerular ﬁltration rate or serum creatinine
(Figure 3). Biomarkers such as NGAL, NAG, and KIM-1
have been implicated in tubulointerstitial damage and have
been used to identify acute kidney injury [61–63]. Serum
cystatin C is elevated earlier than creatinine. Furthermore,
while cystatin C in the serum is a marker of reduced
glomerular ﬁltration, urinary cystatin C is a marker of
tubulardysfunction[64].Otherbiomarkersthathaveproven
useful include BNP, IL-18, and Fatty Acid Binding Protein
(FABP). Thus detection of these biomarkers might be used
to diagnose CRS at an earlier time point, facilitate targeted
therapy for CRS by modifying pharmacologic therapy, and
monitor progression of disease. Nevertheless, a higher index
of suspicion for identifying patients at CRS is needed as
testing for biomarkers at this time is expensive.
Tests for volume status and end-organ perfusion are
also useful in the diagnosis of CRS. Bioimpedence vector
analysis is eﬀective at assessing hydration status and BNP
measurement provides an assessment of cardiac ﬁlling,
although it is often elevated in patients with AKI without
overt ﬂuid overload. Urine sediment examination should
be performed in diﬀerentiating CRS from other causes
of AKI by excluding pathologic cells, casts, or crystals.
Hyponatremia, when present, may indicate excess ADH and
portend an overall poor prognosis. Although patients with
ADHFhaveapoorprognosistobeginwith,ensuingAKIthat
accompanies the CRS confers an even more dire condition.
6. Therapies for the Cardiorenal Syndrome
In patients with ADHF who present with worsening kidney
function, management is challenging and eﬀective therapies
are lacking [66]. This is in large part due to the exclusion
of patients with kidney dysfunction in many of the trials
analyzing treatment for heart failure. A rational approach
would be multi-modal, focusing on the underlying patho-
physiologyofCRSwiththegoalofdisruptingthecardiorenal
connections. Ideally, therapy for CRS would prevent the
fulminant decompensation that jeopardizes kidney function.
This requires use of biomarkers in appropriate settings to
detect early changes in kidney function, and represents an
opportunity for initiation of immediate treatment.
6.1. Diuretics. Although diuretics have a major role in the
symptomatic treatment of heart failure, their eﬀectiveness
is limited due to diuretic resistance in CRS. Although
renal hypoperfusion may require a reduction in the dose
of diuretics, venous congestion may necessitate additional
diuresis. Thus, delicate ﬂuid management may involve
monitoringurineﬂow,centralvenouspressures,andpossible
cardiac output to optimize renal physiology. Nevertheless,
CVP monitoring is cumbersome and costly. A forthcoming
trial, “Determining Optimal Dose and Duration of Diuretic
Treatment in People With Acute Heart Failure (DOSE-AHF)
study,” is designed to answer these questions with regard to
the role of diuretics in CRS [67].
6.2. Natriuretic Peptides. S e v e r a ls t u d i e sh a v ee x p l o r e dt h e
pharmacologic properties of natriuretic peptides in the
treatment of heart failure. Nesiritide, a recombinant natri-
uretic peptide, decreases preload, after load, and pulmonary
vascular resistance, while inducing diuresis. Because of its
natriuretic and aquaretic properties, these agents seem to
be an ideal candidate to relieve the venous congestion in
CRS. Nevertheless, no studies have shown beneﬁt on kidney
function. In fact, a meta-analysis demonstrated poorer renal
outcomes with nesiritide [68]. In one study, nesiritide when
compared to placebo had no eﬀect on glomerular ﬁltration
rate, renal plasma ﬂow, urine output, and sodium excretion
in patients with CRS [69]. To address these controversies,
the “Acute Study of Clinical Eﬀectiveness of Nesiritide in
Decompensated Heart Failure Trial (ASCEND)” is underway
[70].
6.3.VasopressinAntagonists. Bymakinguseoftheiraquaretic
properties, vasopressin (V2 receptor) antagonists have been
used in severe heart failure. However, clinical trials such as
the “Eﬃcacy of Vasopressin Antagonism in Heart Failure
Outcome Study With Tolvaptan (EVEREST)” trial showed6 International Journal of Nephrology
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Figure 2: Hypothetical vicious circle of decreased glomerular function, endothelial injury, and tubular damage in heart failure. GFR:
glomerular ﬁltration rate. NGAL: neutrophil gelatinase associated lipocalin. NAG: N-acetyl-beta-D-glucosaminidase. KIM-1: kidney injury
molecule 1. Adapted and reprinted with permission from Norman and Fine [59] and Damman et al. [60].
no beneﬁt of tolvaptan, a vasopressin antagonist, on all-
cause mortality or the combined end point of cardiovascular
mortality or hospitalization for ADHF [56]. Kidney function
remained stable throughout this trial, and the use of vaso-
pressin antagonists in the CRS conundrum may be limited to
thosepatientscomplicatedbyhyponatremia.Althoughother
studies showed there was some renal beneﬁt [71], the cost
of these medications would prohibit them from being used
routinely.
6.4. Adenosine Antagonist. Adenosine is generated locally in
the macula densa in response to diuretics that block sodium
and chloride absorption, resulting in aﬀerent arteriolar
constriction and decreased GFR. Antagonizing adenosine
might have a role in preserving kidney function in CRS. To
this extent, KW-3902, an adenosine A1-receptor antagonist,
was found to improve kidney function and decrease diuretic
resistance in patients with ADHF and CRS [72].
6.5. Ultraﬁltration. Ultraﬁltration is usually reserved for
diuretic resistance in patients with ADHF. However, in CRS
it might have an early role by rapidly reducing venous
pressure. In two trials of ultraﬁltration in patients with
ADHF, the “Relief for Acutely Fluid-Overloaded Patients
With Decompensated Congestive Heart Failure (RAPID-
CHF)” and “Ultraﬁltration Versus Intravenous Diuretics for
Patients Hospitalized for Acute Decompensated Congestive
Heart Failure (UNLOAD),” there was marked weight loss
a n dr e l i e fo fh e a r tf a i l u r es y m p t o m s[ 73, 74], but no
improvement of kidney function. Nevertheless, published
case reports have shown improved kidney function with
ultraﬁltration[75].Aﬁnalverdictmightcomewiththemuch
awaited “Cardiorenal Rescue Study in Acute Decompensated
Heart Failure (CARRESS-HF)” study which will assess the
eﬀectiveness of ultraﬁltration in ADHF and CRS [76].
6.6. Inotropes. Although the use of inotropes in systolic
heart failure may improve the EAFV and cardiac output,
the inherent adverse eﬀects of these agents, including
arrhythmias and myocardial ischemia, have limited their
utility. In fact, the “Outcomes of a Prospective Trial of
Intravenous Milrinone for Exacerbations of Chronic Heart
Failure (OPTIME-CHF)” trial revealed increased mortality
and poorer outcomes in the milrinone arm [77].
Levosimendan, a phosphodiesterase inhibitor, has been
studied in CRS. In one study, levosimendan resulted in
improved GFR when compared to dobutamine [78]. How-
ever, another study of levosimendan and dobutamine did
not show any beneﬁt [79]. At this time, the role of inotropic
agents in CRS remains unknown.
6.7. Neurohormonal Blockade. The role of RAAS blockade
with ACE inhibitors, ARB, direct renin inhibitors, or aldos-
teroneantagonistsinCRSisalsounclear.WhilemostoftheseInternational Journal of Nephrology 7
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Figure 3: Urinary biomarker proﬁles in subjects who develop AKI
after cardiopulmonary bypass (CPB) surgery. Abbreviations: AKI:
acute kidney injury, deﬁned as a 50% increase in serum creatinine
frombaseline;NGAL:neutrophilgelatinaseassociatedlipocalin;IL-
18: interleukin 18; KIM-1: kidney injury molecule 1; L-FABP: liver-
type fatty acid binding protein; Cys: cystatin c; creat: creatinine.
Adapted and modiﬁed with permission from Devarajan [65].
medicationscauseanacutedropinGFRthroughthedilatory
eﬀectontheeﬀerentarteriole,theyhavelong-termreno-and
cardioprotective eﬀects. Therefore, patients who are prone
t od e v e l o pC R Sy e ta b l et ot o l e r a t eas m a l lr e d u c t i o ni n
GFR, up to 30% from the baseline, may beneﬁt from these
agents. As RAAS has been implicated in oxidative damage, its
interruption though ACE inhibition or angiotensin blockade
may prevent the development of CRS.
Similar to RAAS blockade, beta blockers through their
eﬀectontheSNSmayhavearoleinthelong-termprevention
of adverse cardiac events and in remodeling. However in
CRS, their role is limited by the altered hemodynamics.
Unless the underlying etiology of ADHF is myocardial
infarction, beta blockers are often held until the patients are
hemodynamically stable.
7. Summary
Cardiorenal syndrome represents a disruption of the robust
relationship between the kidneys and the heart to preserve
hemodynamics and maintain organ function. Despite the
ability to adjust ﬁlling pressures, afterload, inotropy, cardiac
output, and volume status in order to compensate for a
wide range of perturbations, dysfunction in either of these
organs creates a susceptibility to dysfunction in the other.
ThemechanismsforworseningkidneyfunctioninADHFare
likely due to underperfusion from reduced cardiac output,
venous congestion impairing tubular function and glomeru-
lar ﬁltration, and activation of neurohormonal mediators
that eﬀect renal blood ﬂow and glomerular autoregulation.
The RAAS, SNS, and NO pathways are instrumental in
preserving kidney function in compensated HF, but play an
aggravating role once HF acutely worsens.
Measures to reverse kidney dysfunction in ADHF require
the early recognition and immediate treatment of CRS.
Agents that target the physiologic mechanisms of CRS may
be eﬀective in restoring kidney function. These include
diuretics, natriuretic peptides, or ultraﬁltration to reduce
venous congestion, inotropes to augment cardiac output,
and RAAS and SNS blockade. Despite these interventions,
CRS identiﬁes patients at the limits of hemodynamic com-
pensation and most susceptible to increased morbidity and
mortality.
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